

## Major Inflammatory Bowel Disease Treatment Market Trend 2025-2034

The Business Research Company's Inflammatory Bowel Disease Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, February 4, 2025 /EINPresswire.com/ -- Updated 2025 Market Reports Released: Trends,



Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The <u>inflammatory bowel disease treatment market</u> has seen significant growth in recent years. It is expected to expand from \$25.26 billion in 2024 to \$27.45 billion in 2025, with a compound



The Business Research Company's Chorionic Gonadotropin Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034" *The Business Research Company*  annual growth rate (CAGR) of 8.6%. This growth can be attributed to the rising prevalence of inflammatory bowel disease, greater demand for biologics and immunomodulators, advancements in treatment options, an aging population, and heightened awareness of the condition.

How Big Is the <u>Global Inflammatory Bowel Disease</u> <u>Treatment Market</u> Expected to Grow, and What Is Its Annual Growth Rate? The inflammatory bowel disease treatment market is

projected to experience rapid growth in the coming years, reaching \$40.27 billion by 2029, with a compound annual growth rate (CAGR) of 10.1%. This growth is driven by increased investment in research and development, rising demand for biosimilars, a higher incidence of inflammatory bowel disease in emerging markets, greater demand for personalized medicine, and the integration of precision medicine into IBD treatment.

Get Your Free Sample Market Report: <u>https://www.thebusinessresearchcompany.com/sample\_request?id=6704&type=smp</u>

What Is Driving the Growth of the Inflammatory Bowel Disease Treatment Market?

The increasing incidence of Crohn's disease and ulcerative colitis is a key factor driving growth in the inflammatory bowel disease treatment market. Both Crohn's disease and ulcerative colitis are forms of inflammatory bowel disease (IBD) that cause inflammation and sores in the digestive tract. As the number of cases of these conditions rises, the demand for IBD treatments is expected to grow, as they are commonly used to alleviate bowel inflammation and prevent related medical complications.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatmentglobal-market-report

Which Leading Companies Are Driving The Growth Of The Inflammatory Bowel Disease Treatment Market Share?

Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology and Surgery Associates P. A.

What Are The Key Trends Driving The Growth Of The Inflammatory Bowel Disease Treatment Market Size?

Leading companies in the inflammatory bowel disease treatment market are focusing on creating innovative products, such as treatments for moderate to severe active ulcerative colitis, to reach broader customer bases, boost sales, and increase revenue. These treatments often involve medications and, in some cases, surgical interventions for managing moderate to severe active ulcerative colitis.

How Is the Global Inflammatory Bowel Disease Treatment Market Segmented? The inflammatory bowel disease treatment market covered in this report is segmented – 1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes

- 2) By Type: Crohn's Disease, Ulcerative Colitis
- 3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments:

- 1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
- 2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
- 3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
- 4) By IL Inhibitors: Ustekinumab, Guselkumab
- 5) By Anti-Integrin: Vedolizumab, Natalizumab
- 6) By JAK Inhibitors: Tofacitinib, Filgotinib
- 7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

The Leading Region in the Inflammatory Bowel Disease Treatment Market is: North America was the largest region in the inflammatory bowel disease treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. What Is the Inflammatory Bowel Disease Treatment Market?

Inflammatory bowel disease treatment involves the use of anti-inflammatory drugs that are commonly prescribed for mild to moderate ulcerative colitis. These include aminosalicylates like mesalamine (Delzicol, Rowasa, and other brands), balsalazide (Colazal), and olsalazine (Dipentum).

Browse Through More Similar Reports By The Business Research Company: Digestive Enzymes Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/digestive-enzyme-global-market-report</u> Smart Pills Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/smart-pills-global-market-report</u> Microbiome Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/microbiomes-global-market-report</u>

## About The Business Research Company

With more than 15000+ reports across 27 industries spanning over 60+ geographies, The Business Research Company has carved a niche in offering comprehensive, data-rich research, and unparalleled insights. With 1,500,000 datasets, detailed secondary research, and exclusive insights from industry experts, you can get the information you need to stay ahead in the game.

Contact us at: The Business Research Company: <u>https://www.thebusinessresearchcompany.com/</u> Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708

Email us at: info@tbrc.info

Follow us on: LinkedIn: <u>https://in.linkedin.com/company/the-business-research-company</u> YouTube: <u>https://www.youtube.com/channel/UC24\_fl0rV8cR5DxlCpgmyFQ</u> Global Market Model: <u>https://www.thebusinessresearchcompany.com/global-market-model</u>

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook X LinkedIn This press release can be viewed online at: https://www.einpresswire.com/article/782805131

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.